Lubiprostone Induces Claudin-1 and Protects Intestinal Barrier Function

Area of Science:

• Gastroenterology
• Cell Biology
• Pharmacology

Background:

• Lubiprostone, a chloride channel activator, is known to reduce epithelial permeability.
• Its direct effects on intestinal epithelial barrier function and modulation mechanisms remain unclear.
• This study investigates lubiprostone's impact on intestinal barrier integrity in vitro.

Purpose of the Study:

• To evaluate the in vitro effects of lubiprostone on intestinal epithelial barrier function.
• To determine if lubiprostone modulates barrier disruption induced by cytokines and aspirin.
• To investigate the impact of lubiprostone on the expression of tight junction proteins.

Main Methods:

• Caco-2 cells were used to model the intestinal barrier.
• Transepithelial electrical resistance (TEER) and FITC-dextran permeability assays assessed barrier function.
• Immunoblotting was employed to analyze claudin expression.
• Cells were treated with interferon-gamma (IFNγ), interleukin-6 (IL-6), interleukin-1β (IL-1β), and aspirin.

Main Results:

• IFNγ, IL-6, IL-1β, and aspirin significantly impaired barrier function (decreased TEER, increased permeability).
• Lubiprostone dose-dependently improved TEER and reduced permeability against IFNγ-induced damage.
• Lubiprostone did not affect barrier disruption caused by IL-6, IL-1β, or aspirin.
• Lubiprostone significantly upregulated claudin-1 expression, but not claudin-3, claudin-4, occludin, or ZO-1.

Conclusions:

• Lubiprostone effectively mitigates interferon-gamma-induced intestinal epithelial barrier dysfunction.
• The observed improvement in barrier function correlates with increased claudin-1 expression.
• Lubiprostone's direct impact on epithelial barrier integrity is linked to claudin-1 modulation.